<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02875314</url>
  </required_header>
  <id_info>
    <org_study_id>IRB15-00399</org_study_id>
    <nct_id>NCT02875314</nct_id>
  </id_info>
  <brief_title>HeadStart4: Newly Diagnosed Children (&lt;10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors</brief_title>
  <official_title>HeadStart4: Newly Diagnosed Children (&lt;10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation With Randomization to Either Single Cycle or to Three Tandem Cycles of Marrow-Ablative Chemotherapy With Autologous Hematopoietic Progenitor Cell Rescue</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nationwide Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's of Alabama</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nationwide Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective randomized clinical trial, to determine whether dose-intensive tandem&#xD;
      Consolidation, in a randomized comparison with single cycle Consolidation, provides an&#xD;
      event-free survival (EFS) and overall survival (OS). The study population will be high-risk&#xD;
      patients (non-Wnt and non-Shh sub-groups) with medulloblastoma, and for all patients with&#xD;
      central nervous system (CNS) embryonal tumors completing &quot;Head Start 4&quot; Induction. This study&#xD;
      will further determine whether the additional labor intensity (duration of hospitalizations&#xD;
      and short-term and long-term morbidities) associated with the tandem treatment is justified&#xD;
      by the improvement in outcome. It is expected that the tandem (3 cycles) Consolidation&#xD;
      regimen will produce a superior outcome compared to the single cycle Consolidation, given the&#xD;
      substantially higher dose intensity of the tandem regimen, without significant addition of&#xD;
      either short-term or long-term morbidities.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Due to the inferior response and event-free survival data of Regimens D and D2 on &quot;Head Start&#xD;
      III&quot; for all children with supratentorial embryonal tumors, in comparison with the published&#xD;
      data from &quot;Head Start II&quot; with Regimen A2 for metastatic patients, all such patients will&#xD;
      receive the &quot;Head Start II&quot; Induction Regimen A2, on &quot;Head Start 4&quot;, for either three or five&#xD;
      cycles, depending upon whether or not they achieve complete remission by the end of Induction&#xD;
      cycle #3. They will then undergo randomization to either single cycle or three tandem cycles&#xD;
      of Consolidation marrow-ablative chemotherapy with AuHPCR.&#xD;
&#xD;
      Because of the unsatisfactory event-free survival for young children with&#xD;
      non-desmoplastic/extensive nodular medulloblastoma (predominantly non-Shh and non-Wnt&#xD;
      medulloblastoma subgroups) on Regimens D and D2 of &quot;Head Start III&quot;, all these patients will&#xD;
      receive the &quot;Head Start II&quot; Induction Regimen A2 on &quot;&quot;Head Start 4&quot;&quot;, for either three or&#xD;
      five cycles, depending upon whether or not they achieve complete remission by the end of&#xD;
      Induction cycle #3. They will then undergo randomization to either single cycle or three&#xD;
      tandem cycles of Consolidation marrow-ablative chemotherapy with AuHPCR.&#xD;
&#xD;
      Because of the excellent event-free and overall survival for young children with good risk&#xD;
      medullo-blastoma (Shh or Wnt subgroups) treated with up-front &quot;Head Start&quot; chemotherapy&#xD;
      strategies, such patients will undergo risk-tailored reduction of duration of Induction&#xD;
      therapy from five cycles to three cycles of the &quot;Head Start II&quot; Induction Regimen A2 on &quot;Head&#xD;
      Start 4&quot; for patients achieving a complete response to 3 cycles, followed, provided they are&#xD;
      also without evidence of residual tumor following recovery from Induction cycle #3. They will&#xD;
      NOT then undergo randomization, but will follow with a single cycle of Consolidation&#xD;
      marrow-ablative chemotherapy as in &quot;Head Start&quot; studies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2025</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare tandem consolidation vs. single cycle consolidation A</measure>
    <time_frame>5 years</time_frame>
    <description>Dose-intensive tandem Consolidation will be compared with single cycle consolidation via randomization. The randomized consolidations will provide an event-free survival (EFS) analysis after completing &quot;Head Start 4&quot; Induction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare tandem consolidation vs. single cycle consolidation B</measure>
    <time_frame>5 years</time_frame>
    <description>Dose-intensive tandem Consolidation will be compared with single cycle consolidation via randomization. The randomized consolidations will provide an overall survival (OS) analysis after completing &quot;Head Start 4&quot; Induction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Induction Cycle Reduction</measure>
    <time_frame>5 years</time_frame>
    <description>Induction chemotherapy cycles will be reduced in number from five to three for molecularly high-risk medulloblastoma (non-Shh/non-Wnt) and CNS embryonal tumors who achieve a complete response (CR) after three cycles of Induction therapy results in equivalent 3-year EFS. Outcome will be analyzed irrespective of Consolidation assignment (Primary Aim) and compared to historical controls.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uniform Treatment Regimen</measure>
    <time_frame>5 years</time_frame>
    <description>Assess the rate of response of sequential dose-intensive and dose-compressed Induction chemotherapy followed by marrow-ablative chemotherapy and autologous hematopoietic progenitor cell rescue (AuHPCR) for children with medulloblastoma and other CNS embryonal tumors enrolled on the &quot;Head Start 4&quot; study utilizing a uniform treatment regimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapy-Related Hearing Loss Evaluation A</measure>
    <time_frame>5 years</time_frame>
    <description>The prevalence and severity of therapy-related hearing loss as a function of cumulative dosing of cisplatin (three versus five cycles during Induction) will be evaluated. Distortion-Product Oto-acoustic Emissions (DPOAE) will be used as an early predictor of hearing loss to identify at-risk patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapy-Related Hearing Loss Evaluation B</measure>
    <time_frame>5 years</time_frame>
    <description>The prevalence and severity of therapy-related hearing loss as a function of AuHPCR (one versus three tandem transplants in Consolidation) will be evaluated. Distortion-Product Oto-acoustic Emissions (DPOAE) will be used as an early predictor of hearing loss to identify at-risk patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological effects will be evaluated using age based tests and questionnaires.</measure>
    <time_frame>5 years</time_frame>
    <description>The long-term neuropsychological effects will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endocrine studies will be conducted using Serum-free T4, TSH, Cortisol, IGF and IGFBP3 laboratory tests.</measure>
    <time_frame>5 years</time_frame>
    <description>The long-term endocrine functions effect will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical growth will be evaluated by collecting patient's height, weight and BSA.</measure>
    <time_frame>5 years</time_frame>
    <description>The long-term physical growth effect will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The development of second neoplasms will be monitored.</measure>
    <time_frame>5 years</time_frame>
    <description>The long-term development of second neoplasms will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropathology Biorepository and Clinical Database</measure>
    <time_frame>5 years</time_frame>
    <description>The study will establish a &quot;Head Start 4&quot; repository of clinical, radiographic and biologic specimens, including nucleic acids derived from these specimens, for future genomic, biologic and pharmacologic research.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Medulloblastoma</condition>
  <condition>Central Nervous System Embryonal Tumors</condition>
  <arm_group>
    <arm_group_label>Induction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The 5 chemotherapy drugs used in the Induction part of treatment are vincristine, cisplatin, cyclophosphamide, etoposide and high-dose methotrexate.&#xD;
Three medications are also given to help reduce the side effects of the chemotherapy drugs. Filgrastim will be given through a vein or through a tiny needle into the tissue just under the skin to help blood counts recover after the chemotherapy. Mesna will be given through a vein with cyclophosphamide to help prevent bleeding in the bladder. Leucovorin will be given through a vein after the methotrexate to protect the body from the side effects of the methotrexate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Cycle Intensive Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The three drugs to be used in this research study are thiotepa, etoposide and carboplatin. These drugs will be given over 6 days to help kill the cancer cells. After 72 hours from getting these drugs, previously collected and frozen blood cells will be thawed and returned through the venous catheter.&#xD;
Carboplatin is given by vein over 4 hours. Thiotepa is given by vein over 3 hours. Etoposide is given by vein over 3 hours. The schedule for these drugs is as follows:&#xD;
Day -8: Carboplatin Day -7: Carboplatin Day -6: Carboplatin Day -5: Thiotepa, Etoposide Day -4: Thiotepa, Etoposide Day -3: Thiotepa, Etoposide Day -2: Rest Day -1: Rest Day 0: Re-infusion of blood cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tandem 3 Cycle Intensive Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The 2 drugs to be used in this treatment are thiotepa and carboplatin. These drugs will be given over 2 days to help kill the cancer cells. After 72 hours from getting these drugs, previously collected and frozen blood cells will be thawed and returned through the venous catheter.&#xD;
Day -4: Thiotepa, Carboplatin Day -3: Thiotepa, Carboplatin Day -2: Rest Day -1: Rest Day 0: Re-infusion of blood cells.&#xD;
Following recovery from the first cycle of this chemotherapy, about 28 days following the Day 0 reinfusion of blood cells, the same cycle will be repeated again. A total of 3 cycles of this therapy will be administered, over the course of 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Induction</intervention_name>
    <description>vincristine, cisplatin, cyclophosphamide, etoposide, high-dose methotrexate</description>
    <arm_group_label>Induction</arm_group_label>
    <other_name>vincristine, cisplatin, cyclophosphamide, etoposide, high-dose methotrexate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Single Cycle Intensive Chemotherapy</intervention_name>
    <description>Carboplatin, thiotepa, etoposide</description>
    <arm_group_label>Single Cycle Intensive Chemotherapy</arm_group_label>
    <other_name>Carboplatin, thiotepa, etoposide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tandem 3 Cycle Intensive Chemotherapy</intervention_name>
    <description>Carboplatin, thiotepa</description>
    <arm_group_label>Tandem 3 Cycle Intensive Chemotherapy</arm_group_label>
    <other_name>Carboplatin, thiotepa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients 10 years of age at the time of definitive confirmatory eligible histologic or&#xD;
             cytologic diagnosis of eligible CNS tumor (brain or spinal cord)&#xD;
&#xD;
          -  Patients may not have received irradiation or chemotherapy (except corticosteroids)&#xD;
&#xD;
          -  Have histologically proven diagnosis of medulloblastoma or CNS embryonal tumors of the&#xD;
             brain or spinal cord&#xD;
&#xD;
          -  Medulloblastoma&#xD;
&#xD;
               -  Posterior fossa classic, desmoplastic or extensive nodular or anaplastic/large&#xD;
                  cell medulloblastoma with appropriate and sufficient tumor material (FFPE or snap&#xD;
                  frozen) for proposed assays: all stages, age less than 6 years at diagnosis&#xD;
&#xD;
               -  Posterior fossa classic or anaplastic/large cell medulloblastoma with sufficient&#xD;
                  tumor material (FFPE or snap frozen) for proposed assays: clinically high-stage&#xD;
                  (neuraxis or extra-neural dissemination, M1-4), age greater than 6 years to less&#xD;
                  than 10 years at diagnosis&#xD;
&#xD;
               -  Posterior fossa medulloblastoma, those 6 years of age and above at diagnosis,&#xD;
                  will only be eligible if they have evidence of neuraxis or extraneural&#xD;
                  dissemination. Patients 6 years of age and above with low-stage (standard-risk,&#xD;
                  M0) medulloblastoma will NOT be eligible for this study, irrespective of&#xD;
                  molecular subgroup and extend of local resection&#xD;
&#xD;
          -  CNS Embryonal Tumors:&#xD;
&#xD;
             - Pineoblastoma, CNS neuroblastoma, CNS ganglioneuroblastoma, embryonal tumor with&#xD;
             multi-layered rosettes (ETMR, including embryonal tumor with abundant neuropil and&#xD;
             true rosettes (ETANTR), ependymoblastoma and ETMR not otherwise specified),&#xD;
             medulloepithelioma, CNS embryonal tumor with rhabdoid features (INI1 intact) and CNS&#xD;
             embryonal tumor, not otherwise specified.&#xD;
&#xD;
          -  Must commence Induction chemotherapy within 28 days of the most recent definitive&#xD;
             surgical procedure and within 21 days of the most recent neuro-imaging studies (MRI of&#xD;
             brain, performed with and without gadolinium contrast, and MRI of total spine,&#xD;
             performed with gadolinium contrast) and lumbar CSF cytological examination&#xD;
&#xD;
          -  Patients must have adequate organ functions at the time of registration:&#xD;
&#xD;
               -  Liver: bilirubin less than 1.5 mg/dL (except for patients with Gilbert's Syndrome&#xD;
                  of indirect hyperbilirubinemia) and transaminases [SGPT or ALT, and SGOT or AST]&#xD;
                  less than 2.5 (two and a half) times the upper limits of institutional normal.&#xD;
&#xD;
               -  Renal: Creatinine clearance and/or glomerular filtration rate (GFR) greater than&#xD;
                  or equal to 60 mL/min/1.73m² within 21 days of protocol therapy.&#xD;
&#xD;
               -  Bone Marrow Function:&#xD;
&#xD;
                    1. Peripheral absolute phagocyte count (APC) &gt; 1000/ µL. APC = numbers of&#xD;
                       banded neutrophils + segmented neutrophils + metamyelocytes + monocytes +&#xD;
                       eosinophils Please note, if institution reports differential as a&#xD;
                       percentage, then APC = [percentage of banded neutrophils + segmented&#xD;
                       neutrophils+ metamyelocytes+monocytes+eosinophils] x total white cell count.&#xD;
&#xD;
                    2. Platelet Count &gt; 100,000/µL (transfusion independent)&#xD;
&#xD;
                    3. Hemoglobin &gt; 8 gm/dL (may have received RBC transfusions).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients older than 10 years of age at time of diagnosis&#xD;
&#xD;
          -  Following diagnoses are not eligible for study enrollment: CNS atypical&#xD;
             teratoid/rhabdoid tumor (AT/RT); all ependymomas including anaplastic ependymomas of&#xD;
             the brain or spinal cord; all choroid plexus carcinomas; all high-grade glial and&#xD;
             glio-neuronal tumors; all primary CNS germ cell tumors; all primary CNS sarcomas; all&#xD;
             primary or metastatic CNS lymphomas and solid leukemic lesions (i.e., chloromas,&#xD;
             granulocytic sarcomas).&#xD;
&#xD;
          -  Patients with unbiopsied diffuse intrinsic pontine tumors will NOT be eligible for&#xD;
             this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Randal Olshefski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nationwide Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathan Finlay, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Global Neuro-Oncology, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Girish Dhall, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Children's of Alabama at UAB</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Megan Blue, MPH</last_name>
    <phone>614-722-3686</phone>
    <email>megan.blue@nationwidechildrens.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Melinda Triplet, RN</last_name>
    <phone>614-722-6039</phone>
    <email>melinda.triplet@nationwidechildrens.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory Friedman, MD</last_name>
      <phone>205-638-9285</phone>
      <email>GFriedman@peds.uab.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Bielamowicz, MD</last_name>
      <phone>501-364-1494</phone>
      <email>KJBielamowicz2@uams.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Care Health Services</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Kramer, MD</last_name>
      <phone>833-675-5437</phone>
      <email>kramerk@MSKCC.ORG</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92350</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert Kheradpour, MD</last_name>
      <phone>909-558-4076</phone>
      <email>akheradpour@llu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tom B Davidson, MD</last_name>
      <phone>310-825-9124</phone>
      <email>tdavidson@chla.usc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mattel Children's Hospital (UCLA)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theodore Moore, MD</last_name>
      <phone>310-825-0867</phone>
      <email>TBMoore@mednet.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCSF Oakland Benioff</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Hastings, MD</last_name>
      <phone>510-428-3631</phone>
      <email>caroline.hastings@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>91868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chenue Abongwa, MD</last_name>
      <phone>714-509-8636</phone>
      <email>Chenue.Abongwa@choc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Dorris, MD</last_name>
      <phone>720-777-8314</phone>
      <email>Kathleen.Dorris@childrenscolorado.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nemours Center for Cancer and Blood Disorders</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Walter, MD</last_name>
      <phone>302-651-5500</phone>
      <email>andrew.walter@nemours.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugene Hwang, MD</last_name>
      <phone>202-476-2800</phone>
      <email>ehwang@childrensnational.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shands Children's Hospital/ University of FL</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sridharan Gururangan, MD</last_name>
      <phone>312-294-8347</phone>
      <email>Sridharan.Gururangan@neurosurgery.ufl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nemours Center for Cancer and Blood Disorders</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael J Joyce, MD, PhD</last_name>
      <phone>904-697-3793</phone>
      <email>michael.joyce@nemours.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nicklaus Children's Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ziad Khatib, MD</last_name>
      <phone>305-662-8360</phone>
      <email>ziad.khatib@mch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orlando Health</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Smith, MD</last_name>
      <phone>321-841-8588</phone>
      <email>Amy.Smith@orlandohealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>John's Hopkins All Children's Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacie Stapleton, MD</last_name>
      <phone>727-767-4176</phone>
      <email>stacie.stapleton@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Mazewski, MD</last_name>
      <phone>404-213-7777</phone>
      <email>Claire.Mazewski@choa.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Riley Children's Hospital/University of Indiana</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Coven, MD</last_name>
      <phone>317-944-8784</phone>
      <email>scoven@iu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospital and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariko Sato, MD</last_name>
      <phone>319-353-3696</phone>
      <email>mariko-sato@uiowa.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Louisville School of Medicine</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Huang, MD</last_name>
      <phone>502-852-8450</phone>
      <email>mchuan01@exchange.louisville.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>John's Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Cohen, MD</last_name>
      <phone>410-614-5055</phone>
      <email>kcohen@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Chi, MD</last_name>
      <phone>617-632-4386</phone>
      <email>Susan_Chi@dfci.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carl Koschmann, MD</last_name>
      <phone>734-615-2736</phone>
      <email>ckoschma@med.umich.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hamza Gorsi, MD</last_name>
      <phone>831-487-5861</phone>
      <email>hgorsi@wayne.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helen DeVos Children's Hospital</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert Cornelius, MD</last_name>
      <phone>616-267-1925</phone>
      <email>albert.cornelius@spectrumhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Bendel, MD</last_name>
      <phone>612-813-6835</phone>
      <email>Anne.Bendel@childrensmn.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Masonic Children's Hospital/University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Moertel, MD</last_name>
      <phone>614-625-3229</phone>
      <email>moert001@umn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Cluster, MD</last_name>
      <phone>314-454-6018</phone>
      <email>acluster@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Specialty Care of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph L Lasky III, MD</last_name>
      <phone>702-732-1493</phone>
      <email>jlasky@cure4thekids.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Joseph Sanzari Children's Hospital/ Hackensack University</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Derek Hanson, MD</last_name>
      <phone>551-996-5437</phone>
      <email>Derek.hanson@hackensackmeridian.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Morristown Medical Center, Atlantic Health System</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Halpern, MD</last_name>
      <phone>973-971-6720</phone>
      <email>steven.halpern@atlantichealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwell Health</name>
      <address>
        <city>Hempstead</city>
        <state>New York</state>
        <zip>11549</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Atlas P Mark, MD</last_name>
      <phone>718-470-3000</phone>
      <email>Matlas@northwell.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Gardner, MD</last_name>
      <phone>212-263-9913</phone>
      <email>sharon.gardner@nyumc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia Presbyterian Children's Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Garvin, MD</last_name>
      <phone>212-305-5808</phone>
      <email>jhg1@columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Kramer, MD</last_name>
      <phone>212-639-6410</phone>
      <email>kramerk@mskcc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Upstate Golisano Children's Hospital/ SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Comito, MD</last_name>
      <phone>315-464-5294</phone>
      <email>comitom@upstate.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeremy Rosenblum, MD</last_name>
      <phone>914-594-2137</phone>
      <email>Jeremy_Rosenblum@nymc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carolina's HealthCare System/Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chad Jacobsen, MD</last_name>
      <phone>704-381-9900</phone>
      <email>chad.jacobsen@carolinashealthcare.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Ashley, MBBS, PhD</last_name>
      <phone>919-684-4164</phone>
      <email>david.ashley@duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akron Children's Hospital</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Rush, MD</last_name>
      <phone>330-543-8730</phone>
      <email>SRush@akronchildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies &amp; Children's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Duncan Stearns, MD</last_name>
      <phone>216-844-3345</phone>
      <email>Duncan.Stearns@uhhospitals.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neha Patel, MD</last_name>
      <phone>216-442-5613</phone>
      <email>Pateln22@ccf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Blue, MPH</last_name>
      <phone>614-722-3686</phone>
      <email>megan.blue@nationwidechildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Parth Patel, MPH</last_name>
      <phone>614-722-4319</phone>
      <email>parth.patel2@nationwidechildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>Randal Olshefski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dayton Children's Hospital</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lionel C Chow</last_name>
      <phone>937-641-5102</phone>
      <email>chowL@childrensdayton.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Children's Hospital</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Greiner, MD</last_name>
      <phone>717-531-6012</phone>
      <email>rgreiner1@pennstatehealth.psu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristina Cole, MD</last_name>
      <phone>267-426-2285</phone>
      <email>colek@email.chop.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandeepkumar Kuril, MD</last_name>
      <phone>843-792-2957</phone>
      <email>kuril@musc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Esbenshade, MD</last_name>
      <phone>615-322-5000</phone>
      <email>Adam.Esbenshade@vumc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wafik Zaky, MD</last_name>
      <phone>713-745-1862</phone>
      <email>wzaky@mdanderson.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Bruggers, MD</last_name>
      <phone>801-662-1000</phone>
      <email>Carol.Bruggers@imail2.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhihong Wang, MD</last_name>
      <phone>804-828-9605</phone>
      <email>Zhihong.Wang@vcuhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>American Family Children's Hospital/University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neha Patel, MD</last_name>
      <phone>608-263-6200</phone>
      <email>npatel@pediatrics.wisc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>58226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryuma Tanaka, MD</last_name>
      <phone>414-607-5280</phone>
      <email>rtanaka@mcw.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>B.C. Children's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvia Cheng, MD, FRCPC</last_name>
      <phone>604-875-2345</phone>
      <phone_ext>2406</phone_ext>
      <email>Sylvia.Cheng@cw.bc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alberta Children's Hospital</name>
      <address>
        <city>Calgary</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucie Lafay-Cousin, MD</last_name>
      <phone>403-955-2554</phone>
      <email>Lucie.Lafay-Cousin@albertahealthservices.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stollery Children's Hospital</name>
      <address>
        <city>Edmonton</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bev Wilson, MD</last_name>
      <phone>780-407-8798</phone>
      <email>bev.wilson@albertahealthservices.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Hospital of Sick Children</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Wall, MD</last_name>
      <phone>416-813-7654</phone>
      <phone_ext>202349</phone_ext>
      <email>donna.wall@sickkids.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Starship Children's Hospital</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Tsui, MB, ChB, FRACP</last_name>
      <phone>(09) 307 4949</phone>
      <phone_ext>22440</phone_ext>
      <email>KarenT@adhb.govt.nz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Christchurch Children's Hospital</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Dodgshun, MD</last_name>
      <phone>+64 33640 640</phone>
      <phone_ext>80198</phone_ext>
      <email>Andrew.dodgshun@cdhb.health.nz</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 27, 2016</study_first_submitted>
  <study_first_submitted_qc>August 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2016</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Medulloblastoma</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

